Priced at Rs 5995 for weekly therapy, Zydus Cadila Launches affordable prostate cancer drug Obnyx in India
In a step that can significantly reduce treatment costs by almost 70%, the drug is priced at Rs 5995 (weekly therapy) reducing the monthly treatment cost to less than Rs. 27000
Ahmedabad: Zydus Cadila has announced that it has launched Enzalutamide, a highly effective drug for the treatment of Prostate Cancer, under the brand name 'Obnyx' in India.
In a step that can significantly reduce treatment costs by almost 70%, the drug is priced at Rs 5995 (weekly therapy) reducing the monthly treatment cost to less than Rs. 27000. The current MRP of Enzalutamide drug ranges from Rs. 70000 to Rs 80000 for a monthly therapy and can be a huge financial burden for elderly patients as they need to continue the therapy for a long period of time. This price reduction will benefit many prostate cancer patients to adhere to the treatment.
One of the important aspects of prostate cancer treatment is reducing the effect of androgens (a male reproductive hormone) on the prostate gland. Many patients require Androgen Receptor Targeted Therapies like Enzalutamide which works by blocking the effects of androgen to stop the growth and spread of prostate cancer cells. More importantly, it is a preferred option in patients with significant liver, heart, and kidney diseases which is very common in elderly men. Enzalutamide has the advantage of being taken through the oral route. Zydus' Obnyx scores over other formulations in the market as it is a soft gel capsule filled with liquid, similar to the innovator drug. This has been specially developed through in-house efforts. The other formulations available in the market are hard gelatin capsules.
Prostate cancer is one of leading cancer in males in India and the risk increases with age. About 1 out of 9 men have a risk of developing prostate cancer in a lifetime. The incidence is nearly 60% in men over the age of 65 years.
Other risk factors such as obesity, family history, and improper diet have been identified as the main contributing factors towards an increased incidence of prostate cancer.
Read also: Zydus Cadila gets USFDA final nod for Deferasirox Tablets for Oral Suspension
